Longitudinal analysis of the relation of dopamine agonist use with impulse control disorders in Parkinson’s disease
Objective: To investigate the longitudinal relationship between dopaminergic therapies and impulse control disorders (ICD) in PD. Background: ICD are frequently associated with dopaminergic therapy, particularly dopamine…Impulse Control Disorders in Parkinson’s Disease: Prevalence and Clinical Features in the Rush University Movement Disorders Clinic
Objective: Investigate the prevalence and characteristics of Impulse Control Disorders (ICDs) in the PD population as compared to non-ICD patients in the Rush University Movement Disorders (RUMD) database.…Examining the brain reserve hypothesis in Parkinson’s disease
Objective: To examine whether brain reserve plays a role in the severity and progression of motor, cognitive, and non-motor symptoms in Parkinson’s disease (PD), by…Impulse Control Disorders in Early Onset and Familial PD
Objective: To characterize impulse control problems in early onset and familial PD (EOPD and FPD). Background: Impulse control disorders are a set of pathological behaviours…An association between impulse control disorders and dopamine agonists in Japanese patients with Parkinson’s disease.
Objective: To evaluate an association between impulse control disorders (ICDs) and dopamine agonists (DA) therapy in Japanese patients with Parkinson’s disease (PD). Background: ICDs such…Successful DBS: Doctors happy, patients not – Why?
Objective: Deep brain stimulation (DBS) in Parkinson's disease (PD) has been proven successful; however, not in all. Background: We report on 5 PD patients who…Impulse control disorder associates with tyrosine hydroxylase 2 gene variants in Parkinson’s disease patients subject to dopaminergic therapy
Objective: The aim of this study was to identify novel genetic variants associated with Impulse control disorder (ICD) manifestation in PD patients subject to dopaminergic…Higher doses of dopamine agonists, impulse control disorders and history of deep brain stimulation (DBS): Risk factors for dopamine agonists withdrawal syndrome (DAWS)?
Objective: To identify risk factors in the development of DAWS in patients with Parkinson's disease (PD). Background: DAWS is often a severe, stereotyped cluster of…Relationship between the MDS-UPDRS and quality of life in Parkinson’s disease: A large international multicenter study of 3206 patients (the QUALPD study)
Objective: To evaluate the relationship between the International Parkinson and Movement Disorder Society – Unified Parkinson's disease Rating Scale (MDS-UPDRS) and Quality of Life (QoL)…EARLYSTIM: STN-DBS alleviates behavioural side effects of dopamine replacement therapy when compared to best medical treatment
Objective: To compare effects of STN-DBS and dopamine replacement therapy (DRT) on behaviour in PD in a 2 year follow-up study. Background: A large panel…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.